XML 52 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Rewrite Acquisition - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Feb. 02, 2022
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Dec. 31, 2021
Business Acquisition [Line Items]            
Research and development   $ 96,651 $ 60,486 $ 319,945 $ 158,646  
Common stock, shares issued   76,587,947   76,587,947   74,485,883
Rewrite Therapeutics Delaware Corporation Member            
Business Acquisition [Line Items]            
Upfront consideration payable in cash $ 45,000          
Research and development 56,000          
Milestone payments 155,000          
Cash $ 130,000          
Common stock, shares issued 25,000,000.0          
Liability for milestone payment $ 10,500     $ 0